ERBB2 and breast neoplasm: Clinical decision-making is strictly focused on evaluating breast tumor cells and is based on assessing hormone receptors and the human epidermal growth factor receptor 2 (Her-2) status using a combination of immunohistochemical and in situ hybridization techniques (1).